PL3248969T3 - Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednich - Google Patents
Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednichInfo
- Publication number
- PL3248969T3 PL3248969T3 PL17176794T PL17176794T PL3248969T3 PL 3248969 T3 PL3248969 T3 PL 3248969T3 PL 17176794 T PL17176794 T PL 17176794T PL 17176794 T PL17176794 T PL 17176794T PL 3248969 T3 PL3248969 T3 PL 3248969T3
- Authority
- PL
- Poland
- Prior art keywords
- oxetan
- aminomethyl
- preparation
- carbamate intermediates
- carbamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| EP15700600.8A EP3097098B1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
| EP17176794.0A EP3248969B1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates |
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3248969T3 true PL3248969T3 (pl) | 2020-06-29 |
Family
ID=52358790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17176794T PL3248969T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednich |
| PL15700600T PL3097098T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[(3-aminooksetan-3-ylo)metylo]-2-(1,1-diokso-3,5-dihydro-1,4-benzotiazepin-4-ylo)-6-metylo-chinazolino-4-aminy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15700600T PL3097098T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[(3-aminooksetan-3-ylo)metylo]-2-(1,1-diokso-3,5-dihydro-1,4-benzotiazepin-4-ylo)-6-metylo-chinazolino-4-aminy |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (pl) |
| EP (2) | EP3248969B1 (pl) |
| JP (1) | JP6397501B2 (pl) |
| KR (1) | KR101841866B1 (pl) |
| CN (2) | CN109879837B (pl) |
| AR (2) | AR099134A1 (pl) |
| AU (1) | AU2015208244B2 (pl) |
| BR (1) | BR112016016978B1 (pl) |
| CA (1) | CA2934225C (pl) |
| ES (2) | ES2788900T3 (pl) |
| HR (2) | HRP20200715T1 (pl) |
| IL (1) | IL245882B (pl) |
| MX (1) | MX368110B (pl) |
| MY (1) | MY176210A (pl) |
| NZ (1) | NZ721534A (pl) |
| PL (2) | PL3248969T3 (pl) |
| RU (1) | RU2664643C2 (pl) |
| SG (1) | SG11201605916QA (pl) |
| SI (2) | SI3097098T1 (pl) |
| WO (1) | WO2015110446A1 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| CN108290882B (zh) | 2015-07-16 | 2021-07-06 | 豪夫迈·罗氏有限公司 | 用于治疗呼吸道合胞病毒感染的4-喹唑啉胺衍生物的晶形 |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CA3077309A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as rsv inhibitors |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| KR102926658B1 (ko) | 2019-03-18 | 2026-02-11 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| AU2020357452B2 (en) | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| CN114728010B (zh) * | 2019-10-31 | 2024-04-30 | 上海爱科百发生物医药技术股份有限公司 | 呼吸道合胞病毒融合蛋白抑制剂组合物以及使用其治疗和预防rsv感染的方法 |
| CN113149977A (zh) | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| IL305189A (en) | 2021-02-26 | 2023-10-01 | Enanta Pharm Inc | Heterocyclic antiviral compounds |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN119285628A (zh) * | 2023-07-10 | 2025-01-10 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| EP1599483A1 (en) * | 2003-02-21 | 2005-11-30 | Pharmacia & Upjohn Company LLC | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo 2.2.1 heptane- 7-carboxylate, intermediates, and process to prepare and isolate them |
| CA2524221A1 (en) * | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| EP2766370B1 (en) | 2011-10-11 | 2016-08-03 | F.Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| EP2997028A1 (en) * | 2013-05-14 | 2016-03-23 | F.Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en not_active Ceased
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3248969T3 (pl) | Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednich | |
| SI3380530T1 (sl) | Izboljšan postopek za pripravo sugamadeksa in njegovih intermediatov | |
| IL250441B (en) | A method for the production of 5-fluoro-1h-pyrazoles starting from hexfluoropropane | |
| PT3717457T (pt) | Processo de preparação de enzalutamida utilizando um intermediário inovador | |
| IL248566A0 (en) | A process for the preparation of 5-fluoro-1h-pyrazoles from hexafluoropropane | |
| GB201416678D0 (en) | Process For Synthesizing Ergothioneine And Its Intermediates | |
| ZA201805871B (en) | An improved process for the preparation of lacosamide | |
| IL255819A (en) | An improved process for the preparation of sofosbuvir and intermediates | |
| SI3565552T1 (sl) | Izboljšan postopek za pripravo rivaroksabana, ki vključuje nov intermediat | |
| ZA201808387B (en) | Improved process for the preparation of carbamates | |
| IL260661B (en) | A process for the preparation of nabivolol intermediates | |
| IL253077A0 (en) | Process and intermediates for the preparation of Fermpanel | |
| ZA201701973B (en) | Process for the preparation of halo-substituted trifluoroacetophenones | |
| GB201510544D0 (en) | New synthesis of tapentadol-hci intermediates | |
| IL237572A0 (en) | Process and intermediates for the preparation of dastinib | |
| PT3102565T (pt) | Processos para a preparação de intermediários de raltegravir | |
| HUP1500603A2 (en) | Process for the separation of 10-deacetyl baccatin iii | |
| IS2977B (is) | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni | |
| GB201700012D0 (en) | Iodoacetylcholine synthesis method as pharmaceutical intermediates | |
| GB201711318D0 (en) | Drug intermediates o-acetaminophen synthesis method | |
| TH1501000743A (th) | กระบวนการสำหรับการสังเคราะห์ของสารมัธยันตร์ของสารปราบวัชพืช ฟลูซีโตซัลฟูรอน |